Featured News
(SWOG) Feb 13, 2021 - In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer –...
(Exelixis) Feb 12, 2021 - Exelixis, Inc. today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating cabozantinib in combination...
(Merck) Feb 13, 2021 - Merck, known as MSD outside the United States and Canada, and Eisai today announced the first presentation of new investigational data from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) in an oral...
(ASCO Daily News) Feb 13, 2021 - The oral hypoxia-inducible factor 2ɑ (HIF-2ɑ) inhibitor belzutifan in combination with cabozantinib offered a promising response rate in patients with advanced clear cell renal cell carcinoma (RCC),...
(ASCO Daily News) Feb 13, 2021 - Treatment with cabozantinib resulted in better progression-free survival (PFS) than sunitinib in the phase II SWOG 1500 study of patients with metastatic papillary renal cell carcinoma (pRCC), while...
More News
(Dana-Farber) Feb 13, 2021 - Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer.
(Pharmaphorum [UK]) Feb 15, 2021 - Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.
(Exelixis) Feb 13, 2021 - Exelixis, Inc. today announced positive phase 2 results for CABOMETYX® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,1 in patients with...
(Yale Cancer Center) Feb 12, 2021 - In a new study led by researchers at Yale Cancer Center (YCC), the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced...
(Evaluate Vantage) Feb 15, 2021 - A little-noticed Merck & Co presentation at Asco-GU over the weekend should be of interest to followers of Arrowhead Pharmaceuticals. It concerns MK-6482, a HIF-2α inhibitor that now carries the INN...
(Exelixis) Feb 12, 2021 - Exelixis, Inc. today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating cabozantinib in combination...
(ICR [UK]) Feb 12, 2021 - Men who have had treatment for early stage testicular cancer could benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging,...
(Yahoo! Finance) Feb 16, 2021 - ImmunityBio, Inc. today announced the oral presentation of "Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in...
(OBR) Feb 13, 2021 - Lenvatinib, combined with either pembrolizumab or everolimus, outperformed sunitinib monotherapy in progression-free survival (PFS) for patients with advanced renal cell carcinoma (RCC), according to findings presented...
(OBR) Feb 13, 2021 - Active surveillance after neoadjuvant chemotherapy may someday be an option for some patients with muscle invasive bladder cancer and certain predictive genomic factors, according to interim findings reported at the...
Follow @OBRTweets